Affected populations: The disorder is believed to affect somewhere between 1 in 12,000 and 1 in 24,000 people, although these figures may be underestimated. Many cases of Angelman syndrome can go ...
Are we medicating or "special educating" young geniuses out of becoming future Einsteins when their late talking is ...
MIDDLETON, Mass., Sept. 22, 2025 /PRNewswire/ -- MavriX Bio, a clinical-stage biotechnology company focused on the development of transformative genetic therapies for Angelman syndrome (AS), today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback